argenx SE (NASDAQ:ARGX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of argenx SE (NASDAQ:ARGX) have been given a consensus rating of “Moderate Buy” by the twenty-three research firms that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $687.00.

A number of analysts recently commented on ARGX shares. JMP Securities boosted their target price on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research report on Tuesday, January 14th. Wells Fargo & Company upped their target price on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Robert W. Baird lifted their price target on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research report on Tuesday, March 4th. William Blair restated an “outperform” rating on shares of argenx in a report on Friday, February 28th. Finally, HC Wainwright lifted their price objective on shares of argenx from $717.00 to $720.00 and gave the company a “buy” rating in a report on Friday, February 28th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ARGX. Charles Schwab Investment Management Inc. boosted its holdings in shares of argenx by 28.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,459 shares of the company’s stock worth $1,875,000 after buying an additional 768 shares during the last quarter. Cerity Partners LLC raised its position in argenx by 20.4% in the third quarter. Cerity Partners LLC now owns 3,273 shares of the company’s stock worth $1,774,000 after acquiring an additional 555 shares during the period. Bank of Montreal Can boosted its stake in argenx by 9.4% in the third quarter. Bank of Montreal Can now owns 8,307 shares of the company’s stock valued at $4,453,000 after acquiring an additional 714 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of argenx by 4,344.2% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 40,842 shares of the company’s stock valued at $22,140,000 after acquiring an additional 39,923 shares during the period. Finally, Hantz Financial Services Inc. increased its stake in shares of argenx by 8.9% during the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company’s stock worth $286,000 after purchasing an additional 43 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Price Performance

NASDAQ ARGX opened at $567.09 on Wednesday. The stock has a market capitalization of $34.46 billion, a P/E ratio of -644.42 and a beta of 0.59. The business has a 50 day simple moving average of $625.68 and a 200 day simple moving average of $602.71. argenx has a one year low of $352.77 and a one year high of $678.21.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. Equities analysts expect that argenx will post 3.13 earnings per share for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.